SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors and innovative specialty delivery systems, has entered into a non-exclusive co-marketing partnership agreement with Lifecore Biomedical, a fully integrated contract development and manufacturing organisation (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials.
Through this partnership, Lifecore becomes a member of SHL鈥檚 recently announced Alliance Management programme, an initiative created to further strengthen SHL鈥檚 vertically integrated business model by facilitating customer engagement with other key players within the drug delivery ecosystem.
SHL and Lifecore will, pursuant to the terms of its agreement, exchange knowledge and experience in their respective fields, enabling both companies to provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.
As the leader and pioneer of autoinjectors, SHL offers drug delivery device solutions and vertically integrated capabilities for the development, manufacturing and final assembly of its autoinjector products. The partnership with Lifecore will allow SHL to recommend a trusted CDMO renowned for its proven proficiency and robust quality systems in aseptic pharmaceutical manufacturing and primary container filling, creating a comprehensive support system across all stages of the autoinjector development and commercial lifecycle.
鈥淎s a true partner to pharma and biotech, we believe in providing full end-to-end solutions that enhance patients鈥� quality of life and enable patients鈥� independence,鈥� said Kimberlee Steele, Managing Director of SHL Pharma, SHL Medical鈥檚 final assembly, labelling and packaging business unit in Florida. 鈥淲e are excited to partner with Lifecore to provide high-quality CDMO services matching SHL鈥檚 own high-touch approach to servicing our customers.鈥�
Darren Hieber, senior vice-president of Corporate Development and Partnerships for Lifecore, commented: 鈥淲e are continuously adapting to keep pace with the evolution of healthcare treatments and technologies and our deep expertise in the fill/finish of syringes and vials is a perfect match for SHL鈥檚 products. Our relationship with SHL will expand the breadth of our offerings to our CDMO customers, enabling them to deliver the benefits and convenience of innovative drug delivery systems to their patients worldwide. We are excited to be aligned with an industry leader who has created a business focused on patient-centric solutions through their unique, convenient, high-quality product portfolio.鈥�